Topiramate (Topiramate) Patent Expiration, LOE Window & CMS Spending

Topiramate (Topiramate) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 33 AB generics, $77.8M 2024 CMS Part D & Medicaid spend, and $3,751 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMulti-Source Generic Manufacturers
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors33
2024 CMS Total Public Spend$77.8M
2024 Medicare Part D Spend$40.4M
2024 Medicaid Spend$37.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($3,751 intro WAC)